Trump Administration Moves to Reclassify Cannabis in Major Shift that Could Expand Research

Why It Matters

By recognizing medical cannabis as a Schedule III drug, the federal government legitimizes research and prescription, unlocking new revenue streams and accelerating evidence‑based treatment options.

Key Takeaways

• Cannabis reclassified from Schedule I to Schedule III federally.
• Reclassification applies only to medical‑grade cannabis, not recreational use.
• Physicians can now prescribe federally recognized medical cannabis products.
• Research on cannabis benefits becomes easier under Schedule III status.
• Tax burdens eased for companies operating in the medical cannabis sector.

Summary

The Biden administration announced a sweeping regulatory shift, moving cannabis from Schedule I—reserved for substances with no accepted medical use—to Schedule III, which includes drugs such as codeine‑acetaminophen and certain steroids. The change is limited to federally‑approved medical‑grade cannabis and does not legalize recreational consumption, which remains under state jurisdiction and subject to future DEA review after a 60‑day comment period. The reclassification grants physicians the authority to prescribe cannabis that meets strict medical standards, and it opens the door for more systematic clinical trials by reducing the bureaucratic hurdles that have long hampered research. Companies that produce or distribute medical cannabis will also see relief from the tax penalties imposed under the former Schedule I status, potentially improving profitability and encouraging investment. CNBC’s Bernie Gomez highlighted that while the move is not a full legalization, it represents a “regulated medical substance” framework. Industry insiders note that the shift could accelerate product development, citing examples of pharmaceutical‑grade formulations already in pipeline that now have a clearer path to market. For investors, patients, and policymakers, the decision signals a federal acknowledgment of cannabis’s therapeutic potential, paving the way for broader clinical evidence, expanded market opportunities, and a possible future reassessment of broader drug policy.

Original Description

The Trump administration moved Thursday to reclassify cannabis under federal law, which could significantly expand scientific research into the drug’s medical uses.

CNBC's Brandon Gomez has the details.